The 8-epimer of prostaglandin F2α, a marker of lipid peroxidation and oxidative stress, is decreased in the nipple aspirate fluid of women with breast cancer

International Journal of Cancer

Volumn 120, Issue 9, 2007, Pages 1971-1976

  Mannello, Ferdinando ^a   Tonti, Gaetana A M ^a   Pagliarani, Silvia ^a   Benedetti, Serena ^a   Canestrari, Franco ^a   Zhu, Weizhu ^b   Qin, Wenyi ^b   Sauter, Edward R ^b  

^a UNIVERSITY OF URBINO   (Italy)

^b University of Missouri   (United States)

Author keywords

Breast cancer; Isoprostane; Lipid peroxidation; Malondialdehyde; Nipple aspirate fluids

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ARACHIDONIC ACID; MALONALDEHYDE;

ADULT; ARTICLE; ASPIRATION; BLOOD LEVEL; BREAST CANCER; BREAST DUCT; BREAST MILK; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; EPIMER; FEMALE; HUMAN; INCIDENCE; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MAMMARY GLAND; METABOLIC ACTIVATION; NIPPLE; NIPPLE ASPIRATE FLUID; OXIDATIVE STRESS; PHYSIOLOGY; PRIORITY JOURNAL; SECRETION;

ADULT; AGED; BIOLOGICAL MARKERS; BREAST NEOPLASMS; DINOPROST; FEMALE; HUMANS; LIPID PEROXIDATION; MALONDIALDEHYDE; MIDDLE AGED; MILK, HUMAN; NIPPLES; OXIDATIVE STRESS;

EID: 33947252429     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22522     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics 2006. CA Cancer J Clin 2006;56:106-30.
2. Fabian CJ, Kimler BF, Mayo MS, Khan SA. Breast-tissue sampling for risk assessment and prevention. Endocr Relat Cancer 2005;12: 185-213.
3. Behrend L, Henderson G, Zwacka RM. Reactive oxygen species in oncogenic transformation. Biochem Soc Trans 2003;31:1441-4.
4. Marnett LJ. Oxy radicals, lipid peroxidation and DNA damage. Toxicology 2002;181/182:219-22.
5. Salganik RI. The benefits and hazards of antioxidants: controlling apoptosis and other protective mechanisms in cancer patients and the human population. J Am Coll Nutr 2001;20 (Suppl 5):473-5.
6. Ray G, Batra S, Shukla NK, Deo S, Raina V, Ashok S, Husain SA. Lipid peroxidation, free radical production and antioxidant status in breast cancer. Breast cancer Res Treat 200;59:163-70.
7. Welsch CW. Review of the effects of dietary fat on experimental mammary gland tumorigenesis: role of lipid peroxidation. Free Radic Biol Med 1995;18:757-73.
8. Gago-Dominguez M, Castelao JE, Pike MC, Sevanian A, Haile RW. Role of lipid peroxidation in the epidemiology and prevention of breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:2829-39.
9. Gonenc A, Ozkan Y, Torun M, Simsek B. Plasma malondialdehyde (MDA) levels in breast and lung cancer patients. J Clin Pharm Ther 2001;26:141-4.
10. Kumaraguruparan R, Subapriya R, Kabalimoorthy J, Nagini S. Antioxidant profile in the circulation of patients with fibroadenoma and adenocarcinoma of the breast. Clin Biochem 2002;35:275-9.
11. Khanzode SS, Muddeshwar MG, Khanzode SD, Dakhale GN. Antioxidant enzymes and lipid peroxidation in different stages of breast cancer. Free Radic Res 2004;38:81-5.
12. Yeh CC, Hou MF, Tsai SM, Lin SK, Hsiao JK, Huang JC, Wang LH, Wu SH, Hou LA, Ma H, Tsai LY. Superoxide anion radical, lipid peroxides and antioxidant status in the blood of patients with breast cancer. Clin Chim Acta 2005;361:104-11.
13. Erten Sener D, Gonenc A, Akinci M, Torun M. Lipid peroxidation and total antioxidant status in patients with breast cancer. Cell Biochem Funct, in press. DOI 10.1002/cbf.1308
14. Kumaraguruparan R, Kabalimoorthy J, Nagini S. Correlation of tissue lipid peroxidation and antioxidants with clinical stage and menopausal status in patients with adenocarcinoma of the breast. Clin Biochem 2005;38:154-8.
15. Tas F, Hansel H, Belce A, Ilvan S, Argon A, Camlica H, Topuz E. Oxidative stress in breast cancer. Med Oncol 2005;22:11-15.
16. Seven A, Erbil Y, Seven R, Inci F, Gulyasar T, Barutcu B, Candan G. Breast cancer and benign breast disease patients evaluated in relation to oxidative stress. Cancer Biochem Biophys 1998;16:333-45.
17. Gonenc A, Erten D, Aslan S, Akinci M, Simsek B, Torun M. Lipid peroxidation and antioxidant status in blood and tissue of malignant breast tumor and benign breast disease. Cell Biol Int 2006;30:376-80.
18. Sauter ER, Ross E, Daly M, Klein-Szanto A, Engstrom PF, Sorling A, Malick J, Ehya H. Nipple aspirate fluid: a promising non-invasive method to identify cellular markers of breast cancer risk. Br J Cancer 1997;76:494-501.
19. Petrakis NL. Physiologic, biochemical, and cytologic aspects of nipple aspirate fluid. Breast Cancer Res Treat 1986;8:7-19.
20. Petrakis NL. Studies on the epidemiology and natural history of benign breast disease and breast cancer using nipple aspirate fluid. Cancer Epidemiol Biomarkers Prev 1993;2:3-10.
21. Mannello F, Sebastiani M. Zymographic analyses and measurement of matrix metalloproteinase-2 and -9 in nipple aspirate fluids. Clin Chem 2003;49:1546-50.
22. Agarwal R, Chase SD. Rapid, fluorimetric-liquid chromatographic determination of malondialdehyde in biological samples. J Chromatogr B Biomed Appl 2002;775:121-6.
23. Rossner P, Jr, Gammon MD, Terry MB, Agrawal M, Zhang FF, Teitelbaum SL, Eng SM, Gaudet MM, Neugut AI, Santella RM. Relationship between urinary 15-F2t-isoprostane and 8-oxodeoxyguanosine levels and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2006;15:639-44.
24. Turoli D, Testolin G, Zanini R, Bellu R. Determination of oxidative status in breast and formula milk. Acta Paediatr 2004;93:1569-74.
25. Janero DR. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 1990;9:515-40.
26. 2α in the Nutrition and Breast Health study. Nutr Cancer 2004;50:155-60.
27. 2α in healthy humans. J Nutr 2006;136:1222-8.
28. Kato I, Chen G, Djuric Z. Non-steroidal anti-inflammatory drug (NSAID) use and levels of a lipid oxidation marker in plasma and nipple aspirate fluids. Breast Cancer Res Treat 2006;97:145-8.
29. Malatesta M, Mannello F, Bianchi G, Sebastiani M, Gazzanelli G. Biochemical and ultrastructural features of human milk and nipple aspirate fluids. J Clin Lab Anal 2000;14:330-5.
30. Alexander H, Stegner AL, Wagner-Mann C, Du Bois GC, Alexander S, Sauter ER. Proteomic analysis to identify breast cancer biomarkers in nipple aspirate fluid. Clin Cancer Res 2004;10:7500-10.
31. Ji C, Rouzer CA, Marnett LJ, Pietenpol JA. Induction of cell cycle arrest by the endogenous product of lipid peroxidation, malondialdehyde. Carcinogenesis 1998;19:1275-83.
32. Crankshaw DJ, Rangachari PK. Isoprostanes: more than just mere markers. Mol Cell Biochem 2003;253:125-30.
33. Montuschi P, Barnes PJ, Robersts LJ, II. Isoprostanes: markers and mediators of oxidative stress. FASEB J 2004;18:1791-1800.
34. Dotan Y, Lichtenberg D, Pinchuk I. Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Prog Lipid Res 2004; 43:200-27.
35. Chen G, Djuric Z. Detection of 2,6-cyclolycopene-1,5-diol in breast nipple aspirate fluids and plasma: a potential marker of oxidative stress. Cancer Epidemiol Biomarkers Prev 2002;11:1592-6.
36. Djuric Z, Visscher DW, Heilbrun LK, Chen G, Atkins M, Covington CY. Influence of lactation history on breast nipple aspirate fluid yields and fluid composition. Breast J 2005;11:92-9.
37. Gonzales MJ, Schemmel RA, Gray JI, Dugan L, Jr, Sheffield LG, Welsch CW. Effect of dietary fat on growth of MCF-7 and MDA-MB231 human breast carcinomas in athymic nude mice: relationship between carcinoma growth and lipid peroxidation product levels. Carcinogenesis 1991;12:1231-5.
38. Cejas P, Casado E, Belda-Iniesta C, De Castro J, Espinosa E, Redondo A, Sereno M, Garcia-Cabezas MA, Vara JA, Dominguez-Caceres A, Perona R, Gonzalez-Baron M. Implications of oxidative stress and cell membrane lipid peroxidation in human cancer. Cancer Causes Control 2004;15:707-19.
39. Yang Y, Sharma R, Sharma A, Awasthi S, Awasthi YC. Lipid peroxidation and cell cycle signaling: 4-hydroxynonenal, a key molecule in stress mediated signaling. Acta Biochim Pol 2003;50:319-36.
40. Look MP, Musch E. Lipid peroxides in the polychemotherapy of cancer patients. Chemotherapy 1994;40:8-15.
41. Das UN. Essential fatty acids, lipid peroxidation and apoptosis. Prostaglandins Leukot Essent Fatty Acids 1999;61:157-63.
42. Petrakis NL, Gruenke LD, Craig JC. Cholesterol and cholesterol epoxides in nipple aspirates of human breast fluids. Cancer Res 1981;41: 2563-5.
43. Wrensch MR, Petrakis NL, Gruenke LD, Miike R, Ernster VL, King EB, Hauck WW, Craig JC, Goodson WH, III. Breast fluid cholesterol and cholesterol β-epoxide concentrations in women with benign breast disease. Cancer Res 1989;49:2168-74.
44. Yeh CC, Hou MF, Tsai SM, Lin SK, Hsiao JK, Huang JC, Wang LH, Wu SH, Hou LA, Ma H, Tsai LY. Superoxide anion radical, lipid peroxides and antioxidant status in the blood of patients with breast cancer. Clin Chim Acta 2005;361:104-11.
45. Diaz-Cruz ES, Brueggemeier RW. Interrelationships between cyclooxygenase and aromatase: unravelling the relevance of cyclooxygenase inhibitors in breast cancer. Anticancer Agents Med Chem 2006;6: 221-32.
46. Sauter ER, Schlatter L, Hewett J, Koivunen D, Flynn JT. Lack of effect of celecoxib on prostaglandin E2 concentrations in nipple aspirate fluid from women at increased risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2004;13:1745-50.
47. Roberts LJ, Fessel JP. The biochemistry of the isoprostane, neuroprostane, and isofuran pathways of lipid peroxidation. Chem Phys Lipids 2004;128:173-86.
48. Meric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano JP. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol 2006;59:51-64.
49. Musiek ES, Breeding RS, Milne GL, Zanoni G, Morrow JD, McLaughglin B. Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration. J Neurochem 2006;97:1301-13.
50. Stoll BA. N-3 fatty acids and lipid peroxidation in breast cancer inhibition. Br J Nutr 2002;87:193-8.
51. Kusuhara H, Komatsu H, Sumichika H, Sugahara K. Reactive oxygen species are involved in the apoptosis induced by nonsteroidal antiinflammatory drugs in cultured gastric cells. Eur J Pharmacol 1999; 383:331-7.